secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001551152-24-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q3 EPS $3.00 adjusted (+1.7%), revenue $14.46B (+3.8%); raises 2024 guidance, increases dividend 5.8%
--------------------------------------------------------------------------------

- Adjusted diluted EPS $3.00, up 1.7% YoY; GAAP EPS $0.88, down 12.0%.
- Revenue $14.460B, +3.8% reported (+4.9% operational); Immunology $7.046B (+3.9%) led by Skyrizi (+50.8%) and Rinvoq (+45.3%).
- Raises 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87.
- Increases quarterly dividend 5.8% to $1.64/share, payable Feb 14, 2025 to holders of record Jan 15, 2025.
- Completed acquisition of Cerevel, adding pipeline of complementary neuroscience assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000036/0001551152-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000036/abbv-20241030.htm
  HTML page:      https://secwatch.observer/filing/0001551152-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer